Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stem Cell Differentiation Depends on Epigenetic Gene Silencing

By LabMedica International staff writers
Posted on 10 Jan 2013
A recent paper described the results of experiments designed to help explain the mechanistic basis for gene expression and silencing especially as it relates to stem cell differentiation.

Investigators at the University of North Carolina (Chapel Hill, USA) examined the role of the polycomb-like proteins (PCLs) as related to epigenetic gene silencing.

Polycomb-like proteins are a family of proteins first discovered in fruit flies that can remodel chromatin such that epigenetic silencing of genes takes place. More...
PRC1 and PRC2 (Polycomb Repressive Complex 2) comprise the two classes of PCLs. This complex has histone methyltransferase activity and primarily trimethylates histone H3 on lysine 27 (i.e. H3K27me3), which transcriptionally silences this region of chromatin. PRC2 is required for initial targeting of the genomic region (PRC Response Elements or PRE) to be silenced, while PRC1 is required for stabilizing this silencing and underlies cellular memory of silenced region after cellular differentiation. These proteins, which are present in all multicellular organisms, are required for long term epigenetic silencing of chromatin and have an important role in stem cell differentiation and early embryonic development.

The investigators reported in the December 27, 2012, online edition of the journal Molecular Cell that they had identified the coexistence of H3K36me3, H3K27me3, and PHF19/PCL3 at a subset of poised developmental genes in mouse pluripotent stem cells and demonstrated that PHF19/PCL3 Tudor function was required for optimal repression of these loci. The Tudor domain is an approximately 60-amino acid structure motif that is found in many chromatin proteins, where it mediates interactions with histones (and other proteins), often through binding specific methylated residues. PCL recognition of H3K36me3 promoted intrusion of PRC2 complexes into active chromatin regions to promote gene silencing and modulated the chromatin landscape during development.

"This finding has important implications for both stem cell biology and cancer development, as the same regulatory circuits controlled by PCLs in stem cells are often misregulated in tumors," said senior author Dr. Greg Wang, assistant professor of biochemistry and biophysics at the University of North Carolina. "The identification of a specific PCL in controlling PRC2 in cancer cells suggests we may be able to develop drugs targeting this PCL to regulate PRC2 function in a more controlled manner that may maintain PRC2 function in stem cells while inhibiting it in the tumor."

Related Links:
University of North Carolina




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.